Abstract: In accordance with one aspect of the invention, a hole is formed within an LE array of a PLD by interrupting the LE array base signal routing architecture such that a hole is left for IP function block to be incorporated. An interface region is provided for interfacing the remaining LE array base signal routing architecture to the IP function block.

Abstract: A data processing system includes a scalable encoder including an encoder and a control module. The encoder includes at least two layer encoders and has an encoder configuration determined during initialization. The control module is configured to generate an encoder control code in accordance with transmission conditions of a communication channel, the encoder control code controlling operation of the at least two encoding layers.

Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Abstract: A switching voltage regulator system and method for providing a start-up mode. An on-chip voltage regulator can be integrated with an on-chip digital logic circuit to provide a core supply voltage to the on-chip digital logic circuit along with an off-chip inductor and capacitor. A clock less start-up circuit automatically operates the on-chip voltage regulator in a start-up mode in order to maintain an equilibrium voltage supply with respect to the on-chip digital logic circuit. Such clock less start-up circuit provides soft start-up operation with respect to the on-chip voltage regulator without a clock signal.

Abstract: A peak current controlled switching voltage regulator system and method for providing a self-power down mode. An on-chip voltage regulator integrated into an on-chip digital logic circuit provides a core supply voltage to the on-chip digital logic circuit along with an off-chip inductor. An off-chip regulator connected to the on-chip digital logic circuit provides an external core supply voltage with respect to the on-chip digital logic circuit. A start-up circuit operates the on-chip voltage regulator in a self-power down mode for a predetermined time period when the on-chip regulator is not connected to the off-chip inductor in order to maintain an equilibrium voltage supply with respect to the on-chip digital logic circuit.

Abstract: Circuits, methods, and apparatus that prevent detection and erasure of encoding or encryption keys. These encoding keys may be used to encode a configuration bitstream or other data for an FPGA or other device. An exemplary embodiment of the present invention masks a first key to form an encoding key in order to prevent detection of the first key. In a specific embodiment, the first key is encoded using a second key. The encoded key is used to encode a configuration bitstream or other data. The encoded key is stored on an FPGA or other device. When the device is to be configured, the encoded key is retrieved and used to decode the bitstream or other data. A further embodiment stores an encryption key in a one-time programmable memory (OTP) array to prevent its erasure or modification. The encoding key may be further obfuscated before storage.

Abstract: Techniques are described herein for, among other things, selecting and/or modifying an ad based on an emotional state of a user. The user's emotional state is determined based on the user's online activity. Advertisement(s) are selected and/or modified for provision to the user based on the user's emotional state. An advertisement may be modified in any of a variety of ways. For example, a color that is included in an advertisement may be replaced with a different color. In another example, a color filter may be applied to the advertisement. In yet another example, visual attribute(s) of the advertisement may be modified. Examples of a visual attribute include, but are not limited to, hue, brightness, contrast, and saturation.

Abstract: In accordance with one aspect of the invention, a hole is formed within an LE array of a PLD by interrupting the LE array base signal routing architecture such that a hole is left for IP function block to be incorporated. An interface region is provided for interfacing the remaining LE array base signal routing architecture to the IP function block.

Abstract: The present invention relates to the stable pharmaceutical composition comprising valsartan or a pharmaceutically acceptable salt thereof with mannitol as a filler and povidone as binder. The present invention also relate to the valsartan or pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or amlodipine or both; and optionally one or more additional excipients.

Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Abstract: The present invention relates to the oral solid pharmaceutical composition comprising lamivudine or a pharmaceutically acceptable salt thereof with isomalt as a filler. The present invention also relate to the combination of lamivudine and other Anti-HIV agents. Thus, for example, the present invention provides a stable tablet formulation comprising lamivudine, isomalt, crospovidone, calcium stearate and opadry white.

Abstract: The subject mater herein relates to computer software and client-server based applications and, more particularly, to a mobile business client. Some embodiments include one or more device-agnostic application interaction models and one or more device specific transformation services. Some such embodiments provide one or more of systems, methods, and software embodied at least in part in a device specific transformation service to transform channel agnostic application interaction models to and from device or device surrogate specific formats.

Abstract: Longest Prefix Match (LPM) is implemented using a binary tree based search algorithm. Masked entries are stored in a plurality of binary search engines, wherein each of the binary search engines stores masked entries of a corresponding mask length. A search value is applied to each of the binary search engines in parallel. The search value is masked within each of the binary search engines, thereby creating a plurality of masked search values, each having a masked length equal to the mask length of the corresponding binary search engine. Each of the masked search values is compared with the masked entries of the corresponding binary search engine. An LPM result is selected from the binary search engine that detects a match, and has the longest corresponding mask length. Alternately, each binary search engine stores masked entries of N mask lengths, and N consecutive comparisons are performed to identify the LPM.

Abstract: The subject mater herein relates to computer software and client-server based applications and, more particularly, to a voice business client. Some embodiments include one or more device-agnostic application interaction models and one or more device specific transformation services. Some such embodiments provide one or more of systems, methods, and software embodied at least in part in a device specific transformation service to transform channel agnostic application interaction models to and from device or device surrogate specific formats.

Abstract: Polymorphic crystalline Forms J, K, L, M, and N of esomeprazole sodium.

Abstract: A process for preparing crystalline Form A of tadalafil (I), comprising crystallization from a solution of tadalafil in a solvent comprising a C3-C7 ester, a ketone, dimethylformamide, dimethylsulfoxide, ethanol, acetonitrile, a chlorinated hydrocarbon, t-butanol, N,N-dimethylacetamide, dioxane, N-methyl pyrrolidone, or a mixture of any two or more thereof.

Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, and to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.

Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts, to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.

Abstract: A wireless data network delivers packets from a network router to a mobile station so that each application running on the mobile station receives an adequate quality of service (QoS). The mobile station sends configuration messages to the network router containing prioritized filters associated with each application. The router filters incoming IP packets into IP flows having the appropriate QoS for the corresponding application. The configuration messages consume valuable air interface resources. Network resources are conserved by assigning precedence values to filters in such a way that fewer configuration messages are needed to reorder the filters when new filters are added. Precedence values for existing filters are spread out in one portion of the precedence space. When the precedence values in that portion are insufficient to accommodate new filters with the correct priority, both new and existing filters are reassigned precedence values in an unassigned portion of the precedence space.

Abstract: The present invention relates to a simple and commercially viable process for separation of desired isomers of nebivolol intermediates from a mixture containing undesired isomers of nebivolol intermediates. Thus, (+)-[2R*[1S*,5S*(S*)]]+[2R*[1S*,5R*(R*)]]-?,??-[phenylmethyliminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol] is dissolved in diisopropyl ether at reflux temperature and cooled to below about 30° C. to obtain the desired (+)-[2R*[1S*,5S*(S*)]]-?,??-[phenylmethyliminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol].